<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01452256</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH Nr.2011-0092</org_study_id>
    <nct_id>NCT01452256</nct_id>
  </id_info>
  <brief_title>Desflurane and Its Effect on Postoperative Morbidity and Mortality in Patients Undergoing Thoracic Surgery</brief_title>
  <official_title>Desflurane and Its Effect on Postoperative Morbidity and Mortality in Patients Undergoing Thoracic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Münsterlingen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <brief_summary>
    <textblock>
      Desflurane and its effect on postoperative morbidity and mortality in patients undergoing
      thoracic surgery.

      Halothane, enflurane, isoflurane, sevoflurane, and desflurane are volatile anesthetics, a
      group of general anesthetics. Because of the hypnotic effects of these agents, attention has
      mainly focused on the central nervous system. In the last 10 years, however, numerous studies
      have reported that volatile anesthetic agents interact with membrane structures of the
      myocardium and thereby attenuate cardiac mechanical dysfunction and limit ultrastructural
      abnormality on reperfusion after prolonged ischemia in the myocyte. Anesthetic-induced
      preconditioning has become a main topic in cardiac research worldwide

        -  Trial with medicinal product
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major complications as defined as ≥ grade IIIa according to classification of surgical complications from Dindo et al. after lung resection with one-lung ventilation during hospitalization</measure>
    <time_frame>postoperative phase until discharge; 6 month after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major complications ≥ grade IIIa according to classification of surgical complications from Dindo et al. after dimissio up to 6 months after surgery</measure>
    <time_frame>postoperative phase until discharge, 6 month postoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative inflammatory mediators TNF-α, IL-6, IL-8, sICAM-1, MCP-1, MIP-2 in blood (correlation to complications ≥ grade IIIa according to classification of surgical complications from Dindo et al. during hospitalization)</measure>
    <time_frame>postoperative phase until discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">460</enrollment>
  <condition>Thoracic Surgery</condition>
  <arm_group>
    <arm_group_label>Desflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desflurane for pharmacological conditioning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Propofol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desflurane</intervention_name>
    <description>4-6 Vol %</description>
    <arm_group_label>Desflurane</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol</intervention_name>
    <description>TIVA to achieve BIS value of 40-60</description>
    <arm_group_label>Propofol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria: • Elective thoracic surgery (thoracotomy, thoracoscopy)

          -  Lung resection

          -  One-lung ventilation

          -  Adults (18-80 years of age)

          -  ASA classification I - III

          -  Written consent (signature from patient)

        Exclusion criteria:

          -  Known hypersensitivity or suspected allergy to propofol, soja or egg proteins

          -  Known hypersensitivity to volatile anesthetics (malignant hyperthermia)

          -  Medication with high dosage of statins

          -  Therapy with cyclosporin

          -  Severe renal impairment (GFR &lt; 30 ml/min)

          -  Oral steroid treatment at present or stopped less than 3 months before surgery

          -  Inflammatory processes (non-pulmonary or pulmonary): elevated C-reactive protein level
             (&gt; 20 mg/l) or leukocytosis (leukocytes &gt; 10x103/?l) or body temperature &gt; 37°C)

          -  Pregnancy

          -  Breast feeding

          -  The subject must not be involved in any other clinical trial during the course of this
             trial, nor within a period of 30 days prior to its beginning or 30 days after its
             completion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>01 Studienregister MasterAdmins</last_name>
    <role>Study Director</role>
    <affiliation>UniversitaetsSpital Zuerich</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Beatrice Beck Schimmer, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich, Division of Anaesthesiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 18, 2011</study_first_submitted>
  <study_first_submitted_qc>October 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2011</study_first_posted>
  <last_update_submitted>February 16, 2016</last_update_submitted>
  <last_update_submitted_qc>February 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Desflurane</mesh_term>
    <mesh_term>Isoflurane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

